Biohaven (NYSE:BHVN) reported quarterly losses of $(0.78) per share which missed the analyst consens

First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic eff

Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to B

The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade sec

NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd.

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combina

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga

Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets.

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.

Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-li

Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Mon

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a ne

Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomark

BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addres

Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on

BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-Ig

In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), t

Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t

Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming

Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for

That pundit flagged the stock as a buy. He also expects it to more than double in price.

Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, accor

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after

  On Tuesday, 44 companies hit new 52-week lows.

Here's a roundup of top developments in the biotech space over the last 24 hours:

  Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for it

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched

  Thursday's morning session saw 167 companies set new 52-week highs.

    Before 10 a.m. ET on Tuesday, 128 companies hit new 52-week highs.

    Before 10 a.m. ET on Friday, 115 companies hit new 52-week highs.

    Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.

  Before 10 a.m. ET on Thursday, 258 companies set new 52-week highs.

  Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its fir

Stocks That Hit 52-Week Lows On Monday